Results 181 to 190 of about 865,582 (335)

Registries on transcatheter edge‐to‐edge repair in heart failure: Current evidence and future perspectives

European Journal of Heart Failure, EarlyView.
Clinical evidence in transcatheter edge‐to‐edge valve repair. EF, ejection fraction; eGFR, estimated glomerular filtration rate; EROA, effective regurgitant orifice area; GDMT, guideline‐directed medical therapy; HF, heart failure; HHF, hospitalization for heart failure; LVEDV, left ventricular end‐diastolic volume; MR, mitral regurgitation; MVARC ...
Gianluigi Savarese, Christian Basile, Marianna Adamo, Stefan D. Anker, Antoni Bayes‐Genis, Michael Böhm, Erwan Donal, Gerasimos S. Filippatos, Francesco Maisano, Piotr Ponikowski, Giuseppe M.C. Rosano, Ralph Stephan von Bardeleben, Marco Metra, Javed Butler   +13 more
wiley   +1 more source

Regulation of the renin–angiotensin system in coronary atherosclerosis: A review of the literature

Vascular Health and Risk Management, 2008
Ramadan A Hammoud, Christopher S Vaccari, Sameer H Nagamia, Bobby V KhanEmory University School of Medicine, Division of Cardiology, Grady Memorial Hospital Vascular Research Laboratory, Atlanta, Georgia, USAAbstract: Activation of the renin&ndash ...
Ramadan A Hammoud, Christopher S Vaccari, Sameer H Nagamia, Bobby V Khan   +3 more
doaj  

Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects. [PDF]

, 1981
D. B. Brunner, G Desponds, Jérôme Biollaz, I Keller, F Ferber, Haralambos Gavras, Brunner Hr, JL Schelling   +7 more
openalex   +1 more source

Sacubitril/valsartan versus valsartan initiation in patients naïve to renin–angiotensin system inhibitors: Insights from PARAGLIDE‐HF

European Journal of Heart Failure, EarlyView.
Changes in N‐terminal pro‐B‐type natriuretic peptide and assessment of clinical endpoints according to prior exposure to renin–angiotensin system inhibitors in the Pre‐specified substudy of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE‐HF).
Nina Nouhravesh, Alexander H. Gunn, Derek Cyr, Adrian F. Hernandez, David A. Morrow, Eric J. Velazquez, Jonathan H. Ward, Samiha Sarwat, Kavita Sharma, Kristin M. Williamson, Randall C. Starling, Serge Lepage, Shelley Zieroth, Scott D. Solomon, Robert J. Mentz   +14 more
wiley   +1 more source

Role of the renin-angiotensin system in the control of vasopressin secretion in conscious dogs. [PDF]

, 1986
Virginia L. Brooks, L. C. Keil, I. A. Reid   +2 more
openalex   +1 more source

Resistant hypertension and renal denervation: Who's kidding whom? [PDF]

, 2014
Sever, P
core   +1 more source

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant‐level pooled analysis of the CANVAS and CREDENCE trials

European Journal of Heart Failure, EarlyView.
Among high‐risk patients with T2D, new oral loop diuretic intensification was frequent and portended adverse prognostic significance. Treatment with canagliflozin significantly reduced the need for loop diuretic intensification. ABSTRACT Aims The sodium–glucose cotransporter 2 inhibitor canagliflozin reduces the risk of heart failure (HF ...
Safia Chatur, Muthiah Vaduganathan, Robert A. Fletcher, Vlado Perkovic, Hiddo Heerspink, Clare Arnott, Carol Pollock, Kenneth W. Mahaffey, Bruce Neal, Meg Jardine, Scott D. Solomon, Brendon L. Neuen   +11 more
wiley   +1 more source

The renin-angiotensin system and hypertension

, 1979
Edgar Haber
openalex   +1 more source

Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin‐angiotensin system and sodium excretion in normal man. [PDF]

, 1984
G P Hodsman, JR Zabludowski, Carmine Zoccali, R. Fräser, JJ Morton, Gordon Murray, J. I. S. Robertson   +6 more
openalex   +1 more source

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial

European Journal of Heart Failure, EarlyView.
Baseline characteristics for the vericiguat global study in participants with chronic heart failure (VICTOR) trial. ARNI, angiotensin receptor/neprilysin inhibitor; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; GDMT, guideline‐directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection ...
Clara I. Saldarriaga, Faiez Zannad, Ciaran J. McMullan, Aiwen Xing, Davis Gates, Kevin J. Anstrom, Marc P. Bonaca, Stefano Corda, Justin A. Ezekowitz, Carolyn S.P. Lam, Eldrin F. Lewis, JoAnn Lindenfeld, Robert J. Mentz, Christopher O'Connor, Mahesh Patel, Piotr Ponikowski, Yogesh N.V. Reddy, Giuseppe M.C. Rosano, Michele Senni, James Udelson, Adriaan A. Voors, Javed Butler   +21 more
wiley   +1 more source